

22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

PharmaMar presents 8 posters on its products at 22nd Annual EORTC-NCI-AARC conference

- *PharmaMar presented data on its main drugs at the 22nd EORTC-NCI-ACR Symposium, specifically: Yondelis®, Aplidin®, Zalypsis®, Irvalec® and PM01183*
- *Leading oncology researchers attended the event to share the latest developments in this field*

Madrid, 23 November 2010: PharmaMar, a Grupo Zeltia subsidiary, participated in the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, presenting 8 posters on its main products. The conference, held from 16 to 19 November in Berlin, brought together the world's leading oncology researchers with a view to sharing the latest developments in the field.

PharmaMar presented the following data:

The company's new compound, PM01183, completed Phase I clinical trials in patients with refractory solid tumours. Recruitment was completed in September 2010; 31 patients were treated and the safe, effective recommended dose (RD) for Phase II was determined. The dose was safe, well-tolerated, and exhibited effective anti-tumour activity in different types of tumours.

Trabectedin (Yondelis®) displayed anti-tumour activity in various preclinical models. Clinical research has confirmed that Yondelis® is effective against myxoid liposarcoma (MLS). Yondelis® is initially active (response rate of 50% in patients) against MLS, which is characterised by the FUS-CHOP chimeric protein. A resistant cell line model (402-91/ET) was developed for the first time to investigate the mechanism of resistance to Trabectedin. The initial results show that the mechanism of resistance is potentially attributable to changes in the regulation of FUS-CHOP mediated transcriptions.

Other data presented at the symposium confirm the safety of Aplidin®+bevacizumab (in doses of 3.8 mg/m² APL + 10 mg/kg BEV) in patients

with refractory solid tumours. Factors which motivated this trial include the combination's potential to inhibit angiogenesis at different stages, to reduce risk of resistance, and the lack of toxicity overlap between the two compounds.

The company also presented data demonstrating the rapid cytotoxic effect of Irvalec[®] against tumour cells; the drug induced tumour cell necrosis minutes after being administered. Zalypsis[®] showed *in vivo* anti-tumour activity in an experimental orthotopic model (NP9) of pancreatic cancer.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis[®] is Spain's first antitumour drug. Yondelis[®] is currently approved for STS in 33 countries outside the EEA, and in 10 of those countries for platinum-sensitive ROC as well (including Brazil and Canada). Yondelis[®] is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis[®] are also under way on prostate, breast, lung and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin[®], Irvalec[®], Zalypsis[®] and PM01183. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.

Important note

PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Grupo Zeltia (Spanish stock exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's Electronic Market since 1998. This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information +34 91 444 4500

This note is also available on the PharmaMar web site: www.pharmamar.com and at Zeltia's web site: www.zeltia.com